MX2010008745A - Inhibidor de fibrosis. - Google Patents

Inhibidor de fibrosis.

Info

Publication number
MX2010008745A
MX2010008745A MX2010008745A MX2010008745A MX2010008745A MX 2010008745 A MX2010008745 A MX 2010008745A MX 2010008745 A MX2010008745 A MX 2010008745A MX 2010008745 A MX2010008745 A MX 2010008745A MX 2010008745 A MX2010008745 A MX 2010008745A
Authority
MX
Mexico
Prior art keywords
alkyl
fibrosis inhibitor
optionally substituted
different
same
Prior art date
Application number
MX2010008745A
Other languages
English (en)
Inventor
Koji Murakami
Takuya Taramoto
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2010008745A publication Critical patent/MX2010008745A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El objeto principal de la presente invención es proporcionar un inhibidor de fibrosis. La presente invención se refiere a un inhibidor de fibrosis que contiene el derivado heterocíclico representado por la siguiente fórmula general (1) o una sal farmacéuticamente aceptable del mismo como un ingrediente activo; (ver fórmula (1)) En la fórmula (1), R1 y R2 son los mismos o diferentes y representan cada uno un arilo opcionalmente sustituido; R3 y R4 son los mismos o diferentes y representan cada uno átomo de hidrógeno o alquilo; R5 representa átomo de hidrógeno, alquilo o átomo de halógeno; Y representa N o N?O; A representa NR6, y R6 representa átomo de hidrógeno, alquilo, alquenilo o cicloalquilo; D representa alquileno o alquenileno que está opcionalmente sustituido con hidroxi; E representa fenileno o un enlace individual; G representa O, S, SO o SO2 y.
MX2010008745A 2008-02-28 2009-02-26 Inhibidor de fibrosis. MX2010008745A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008046999 2008-02-28
PCT/JP2009/053582 WO2009107736A1 (ja) 2008-02-28 2009-02-26 線維化抑制剤

Publications (1)

Publication Number Publication Date
MX2010008745A true MX2010008745A (es) 2010-08-30

Family

ID=41016123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008745A MX2010008745A (es) 2008-02-28 2009-02-26 Inhibidor de fibrosis.

Country Status (20)

Country Link
US (3) USRE46364E1 (es)
EP (1) EP2246336B1 (es)
JP (1) JP5522030B2 (es)
KR (1) KR101581059B1 (es)
CN (2) CN104761509A (es)
AU (1) AU2009218115B2 (es)
BR (1) BRPI0908491A2 (es)
CA (1) CA2716554C (es)
CY (1) CY1123308T1 (es)
DK (1) DK2246336T3 (es)
ES (1) ES2817557T3 (es)
HR (1) HRP20201352T1 (es)
HU (1) HUE050786T2 (es)
LT (1) LT2246336T (es)
MX (1) MX2010008745A (es)
PL (1) PL2246336T3 (es)
PT (1) PT2246336T (es)
RU (1) RU2497525C2 (es)
SI (1) SI2246336T1 (es)
WO (1) WO2009107736A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2246336T3 (da) * 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
CN102065864B (zh) * 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
WO2009157396A1 (ja) * 2008-06-23 2009-12-30 日本新薬株式会社 脊柱管狭窄症治療剤
MY163762A (en) 2008-07-23 2017-10-31 Toray Industries Therapeutic agent for chronic renal failure
KR102705198B1 (ko) 2009-06-26 2024-09-11 니뽄 신야쿠 가부시키가이샤 결정
WO2011024874A1 (ja) * 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
AU2016366073B2 (en) 2015-12-02 2021-08-26 Nippon Shinyaku Co., Ltd. Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide
CN109563055B (zh) * 2016-07-29 2021-12-24 成都苑东生物制药股份有限公司 氨基吡嗪类化合物或盐、异构体、其制备方法及用途
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
TWI801421B (zh) 2017-09-28 2023-05-11 日商日本新藥股份有限公司 結晶
US10407396B2 (en) * 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
BR112020008940A2 (pt) 2017-11-16 2020-10-20 Nippon Shinyaku Co., Ltd. preparação de liberação controlada
KR20210040360A (ko) 2018-07-27 2021-04-13 에이알시 메디컬 디바이시즈 인코포레이션 섬유성 유착 치료용 고순도 및/또는 개질 푸칸 조성물
CN108863955B (zh) * 2018-08-03 2021-08-13 成都苑东生物制药股份有限公司 二苯基吡嗪类化合物或其药学上可接受的盐、异构体及其制备方法和用途
JP7541700B2 (ja) * 2019-06-11 2024-08-29 国立大学法人京都大学 腎間質細胞の製造方法
CA3154802A1 (en) 2019-10-23 2021-04-29 Marc Patrik SCHRADER Pharmaceutical composition comprising selexipag
WO2021152060A1 (en) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
WO2024194449A1 (en) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4732096A (en) * 1995-02-27 1996-09-18 Toray Industries, Inc. Remedy for pulmonary heart
WO2002085412A1 (fr) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Inhibiteurs de la fibrose des tissus
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
DK2246336T3 (da) * 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
WO2009157396A1 (ja) * 2008-06-23 2009-12-30 日本新薬株式会社 脊柱管狭窄症治療剤
NO2315587T3 (es) 2008-08-13 2018-03-24
WO2010075861A2 (en) 2008-12-30 2010-07-08 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
KR102705198B1 (ko) * 2009-06-26 2024-09-11 니뽄 신야쿠 가부시키가이샤 결정

Also Published As

Publication number Publication date
US20110015211A1 (en) 2011-01-20
US8889693B2 (en) 2014-11-18
RU2497525C2 (ru) 2013-11-10
US20140221397A1 (en) 2014-08-07
PT2246336T (pt) 2020-07-29
LT2246336T (lt) 2020-08-25
KR101581059B1 (ko) 2015-12-30
AU2009218115B2 (en) 2013-05-30
CY1123308T1 (el) 2021-12-31
JPWO2009107736A1 (ja) 2011-07-07
CN104761509A (zh) 2015-07-08
CA2716554C (en) 2017-01-10
SI2246336T1 (sl) 2020-09-30
US8729086B2 (en) 2014-05-20
EP2246336B1 (en) 2020-07-01
JP5522030B2 (ja) 2014-06-18
ES2817557T3 (es) 2021-04-07
CA2716554A1 (en) 2009-09-03
KR20100135726A (ko) 2010-12-27
AU2009218115A1 (en) 2009-09-03
HUE050786T2 (hu) 2021-01-28
PL2246336T3 (pl) 2020-12-14
USRE46364E1 (en) 2017-04-11
EP2246336A1 (en) 2010-11-03
EP2246336A4 (en) 2011-12-21
CN101959868A (zh) 2011-01-26
DK2246336T3 (da) 2020-07-20
RU2010139644A (ru) 2012-04-10
WO2009107736A1 (ja) 2009-09-03
BRPI0908491A2 (pt) 2015-08-11
HRP20201352T1 (hr) 2020-11-27

Similar Documents

Publication Publication Date Title
MX2010008745A (es) Inhibidor de fibrosis.
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
MY150661A (en) Pyridin-3-yl derivatives as immunomodulating agents
TW200635930A (en) Bicyclic pyrrole derivatives
MY149853A (en) Pyridin-4-yl derivatives as immunomodulating agents
TNSN06255A1 (en) Chemokine receptor antagonists
TW200608972A (en) Aryl-pyridine derivatives
TW200833328A (en) 2-aza-bicyclo[3.1.0]hexane derivatives
ATE493386T1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
WO2009057079A3 (en) Novel pyrimidine derivatives
EP1760073A4 (en) SULPHONAMIDE COMPOUND
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
IL190643A0 (en) Novel dihydropseudoerythromycin derivatives
EP1726584A4 (en) 2-AMINOCHINAZOLINDERIVAT
WO2008096820A1 (ja) ビフェニル誘導体
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
MX2009008756A (es) Compuesto macrociclico.
WO2008114812A1 (ja) Jak阻害剤
WO2009063990A1 (ja) ベンズアゼピノン化合物
WO2007068728A3 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体

Legal Events

Date Code Title Description
FG Grant or registration